DSIP — Peptide Dosing Protocols reference

patient_educationexpert_opinion · status: needs_provider_review

Details

Author: —

Citation: —

Summary (generated — provider review required)

DSIP Peptide Dosing Guide: Timing, Protocol & Safety (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols DSIP Peptide Dosing Guide: Timing, Protocol & Safety (2026) Protocol / Research Dosing Guide DSIP Peptide Dosing Guide: Timing, Protocol & Safety (2026) An evidence-based DSIP protocol guide covering dosing structure, timing, cycle length, and safety considerations for this sleep-focused peptide. By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Product-Specific Link Peptide Partners DSIP Supply View DSIP Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status DSIP Comparisons Related Protocols Blood Tests FAQ References DSIP Quick Start DSIP, or delta sleep-inducing peptide, is a small nine-amino-acid peptide that was first isolated from the cerebral venous blood of sleeping rabbits in the 1970s. It is named for its early observation of promoting delta-wave activity in EEG recordings, the slow brain waves that mark deep non-REM sleep.

The original source document remains the source of truth. Generated summaries are not authoritative.

Linked assets (9) · phenotypes (0)

evidence_reference, dosing_reference, safety_reference, mechanism, monitoring_reference

Findings (130) · awaiting review (86)

regulatory · pending

The FDA flagged theoretical immunogenicity risk in its Category 2 listing.

dosing · pending

Boundary This is not a dosing recommendation.

dosing · pending

By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Product-Specific Link Peptide Partners DSIP Supply View DSIP Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status DSIP Comparisons Related Protocols Blood Tests FAQ References DSIP Quick Start DSIP, or delta sleep-inducing peptide, is a small nine-amino-acid peptide that was first isolated from the cerebral venous blood of sleeping rabbits in the 1970s.

regulatory · pending

The FDA refers to DSIP in the Federal Register as Emideltide .

regulatory · pending

As of September 2023 it is on the FDA's Category 2 list of bulk drug substances that may not be compounded due to significant s

dosing · pending

Route Subcutaneous research-use injection is the most commonly described format.

dosing · pending

Schedule Most community research planning describes a single evening dose 1-3 hours before intended sleep, run for short cycles.

regulatory · pending

Research status Not FDA-approved.

regulatory · pending

DSIP is not FDA-approved and is currently on the FDA Category 2 do-not-compound list.

dosing · pending

This page covers DSIP dose planning and protocol notes.

safety · pending

It covers sleep studies, safety notes, and other options.

dosing · pending

DSIP Dosing Protocol & Schedule Two distinct dosing patterns appear in the DSIP literature.

dosing · pending

Community research planning today is mostly subcutaneous and uses much lo

dosing · pending

wer doses based on tolerability rather than nmol/kg targets.

dosing · pending

The numbers below are reported research-context dose ranges.

dosing · pending

They are not a recommendation, and there is no modern, well-powered, FDA-recognized human trial that establishes a clinically validated dose.

dosing · pending

DSIP Reported Research-Context Dose Ranges Pattern Older human trials Typical Range 25 nmol/kg Route IV Notes Short 4-7 night courses; published 1981-1987 in middle-aged chronic insomniacs.

dosing · pending

Pattern Lower research planning Typical Range 100-200 mcg Route SubQ Notes Most common community range; described in research write-ups, not clinical trials.

dosing · pending

Pattern Higher research planning Typical Range 200-300 mcg Route SubQ Notes Used in some research write-ups; tolerability and side-effect data are sparse.

dosing · pending

Lower research planning 100-200 mcg SubQ Most common community range; described in research write-ups, not clinical trials.

dosing · pending

Higher research planning 200-300 mcg SubQ Used in some research write-ups; tolerability and side-effect data are sparse.

dosing · pending

This is not a dosing recommendation.

dosing · pending

The 25 nmol/kg figure is a published trial protocol, not a community-style mcg dose.

safety · pending

Approach Extended cycle Duration 6-8 weeks Review Point Week 6 Typical Context Less common; long-term safety data is limited.

safety · pending

Extended cycle 6-8 weeks Week 6 Less common; long-term safety data is limited.

safety · pending

Long-term human safety has not been formally established.

safety · pending

Older reviews note limited side effects but the data set is small.

dosing · pending

The cycle math below assumes one evening subcutaneous research-use draw per day from a 10 mg vial reconstituted with 2.0 mL bacteriostatic water.

dosing · pending

DSIP Vials The math below assumes a 10 mg lyophilized vial reconstituted with 2.0 mL BAC water = 5 mg/mL.

dosing · pending

Cycle length Planning note 1 week, 4 weeks 1 x 10 mg vial 1 week: 7 evening draws; comfortable margin for priming losses.; 4 weeks: 28 daily draws; one 10 mg vial covers a standard cycle at ~150-300 mcg/day.

dosing · pending

6-8 weeks 2 x 10 mg vials 6 weeks: 42 daily draws; second vial adds margin for higher-dose planning.; 8 weeks: 56 daily draws with margin for priming loss.

dosing · pending

1 week, 4 weeks 1 x 10 mg vial 1 week: 7 evening draws; comfortable margin for priming losses.; 4 weeks: 28 daily draws; one 10 mg vial covers a standard cycle at ~150-300 mcg/day.

dosing · pending

Insulin Syringes (U-100) 0.3 mL / 30-unit syringes are easiest for the small evening draws DSIP usually requires.

dosing · pending

Bacteriostatic Water 2.0 mL BAC water per 10 mg vial gives a clean 5 mg/mL working concentration.

dosing · pending

Cycle length Planning note 1 week, 4 weeks, 6 weeks, 8 weeks 1 x 10 mL bottle 1 week: 1 vial uses 2 mL total; one bottle gives wide margin.; 4 weeks: 1 vial uses 2 mL total.; 6 weeks: 2 vials use 4 mL total.; 8 weeks: 2 vials use 4 mL total.

dosing · pending

1 week, 4 weeks, 6 weeks, 8 weeks 1 x 10 mL bottle 1 week: 1 vial uses 2 mL total; one bottle gives wide margin.; 4 weeks: 1 vial uses 2 mL total.; 6 weeks: 2 vials use 4 mL total.; 8 weeks: 2 vials use 4 mL total.

dosing · pending

This guide assumes a 10 mg vial.

dosing · pending

Adding 2.0 mL of bacteriostatic water gives a 5 mg/mL working concentration, where 100 mcg equals 2 units on a standard U-100 insulin syringe.

dosing · pending

DSIP Reconstitution Math (10 mg vial) Vial 10 mg BAC water 2.0 mL Concentration 5.0 mg/mL (5,000 mcg/mL) 100 mcg draw 0.02 mL = 2 units 200 mcg draw 0.04 mL = 4 units 300 mcg draw 0.06 mL = 6 units Vial BAC water Concentration 100 mcg draw 200 mcg draw 300 mcg draw 10 mg 2.0 mL 5.0 mg/mL (5,000 mcg/mL) 0.02 mL = 2 units 0.04 mL = 4 units 0.06 mL = 6 units Units shown are U-100 insulin-syringe units.

Processing

Processed into 18 searchable sections.